- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.28 Å
- Oligo State
- monomer
- Ligands
- 1 x HEM: PROTOPORPHYRIN IX CONTAINING FE(Non-covalent)
- 1 x QR8: (3~{R},4~{S},5~{R},6~{S},7~{S},9~{S},11~{R},12~{S},13~{R},14~{R})-3,5,7,9,11,13,14-heptamethyl-4,6,12-tris(oxidanyl)-1-oxacyclotetradecane-2,10-dione(Non-covalent)
- 1 x RAM: alpha-L-rhamnopyranose(Non-covalent)
- 70 x FMT: FORMIC ACID(Non-functional Binders)
FMT.4: 4 residues within 4Å:- Chain A: F.349, H.355, R.363
- Ligands: FMT.47
Ligand excluded by PLIPFMT.5: 4 residues within 4Å:- Chain A: R.35, R.326, D.327, E.328
Ligand excluded by PLIPFMT.6: 5 residues within 4Å:- Chain A: R.125, E.368, S.371, A.372, R.375
Ligand excluded by PLIPFMT.7: 4 residues within 4Å:- Chain A: D.26, L.27, Y.287, R.326
Ligand excluded by PLIPFMT.8: 3 residues within 4Å:- Chain A: P.15, A.16
- Ligands: FMT.11
Ligand excluded by PLIPFMT.9: 4 residues within 4Å:- Chain A: L.389, W.391, Q.393
- Ligands: FMT.13
Ligand excluded by PLIPFMT.10: 3 residues within 4Å:- Chain A: R.123, L.127, E.159
Ligand excluded by PLIPFMT.11: 6 residues within 4Å:- Chain A: V.14, A.16, R.44
- Ligands: FMT.8, FMT.19, FMT.20
Ligand excluded by PLIPFMT.12: 2 residues within 4Å:- Chain A: E.166, D.167
Ligand excluded by PLIPFMT.13: 5 residues within 4Å:- Chain A: V.386, A.387, L.389, W.391
- Ligands: FMT.9
Ligand excluded by PLIPFMT.14: 6 residues within 4Å:- Chain A: V.64, L.65, F.70, T.72, R.298, H.354
Ligand excluded by PLIPFMT.15: 4 residues within 4Å:- Chain A: Q.96, D.100, E.233
- Ligands: FMT.58
Ligand excluded by PLIPFMT.16: 4 residues within 4Å:- Chain A: R.266, L.337, D.338, F.339
Ligand excluded by PLIPFMT.17: 1 residues within 4Å:- Chain A: D.209
Ligand excluded by PLIPFMT.18: 3 residues within 4Å:- Chain A: R.183, Q.393, G.394
Ligand excluded by PLIPFMT.19: 3 residues within 4Å:- Chain A: A.16
- Ligands: FMT.11, FMT.20
Ligand excluded by PLIPFMT.20: 3 residues within 4Å:- Chain A: D.12
- Ligands: FMT.11, FMT.19
Ligand excluded by PLIPFMT.21: 7 residues within 4Å:- Chain A: P.18, P.22, S.292, A.293
- Ligands: FMT.22, FMT.24, FMT.62
Ligand excluded by PLIPFMT.22: 6 residues within 4Å:- Chain A: P.18, S.20, P.22, D.28, R.398
- Ligands: FMT.21
Ligand excluded by PLIPFMT.23: 2 residues within 4Å:- Chain A: P.15, F.19
Ligand excluded by PLIPFMT.24: 4 residues within 4Å:- Chain A: P.18, L.21, T.182
- Ligands: FMT.21
Ligand excluded by PLIPFMT.25: 2 residues within 4Å:- Chain A: F.19, S.20
Ligand excluded by PLIPFMT.27: 1 residues within 4Å:- Ligands: FMT.28
Ligand excluded by PLIPFMT.28: 1 residues within 4Å:- Ligands: FMT.27
Ligand excluded by PLIPFMT.29: 1 residues within 4Å:- Chain A: E.33
Ligand excluded by PLIPFMT.30: 4 residues within 4Å:- Chain A: D.28, P.29, Y.31, A.32
Ligand excluded by PLIPFMT.31: 2 residues within 4Å:- Chain A: D.37, E.38
Ligand excluded by PLIPFMT.32: 4 residues within 4Å:- Chain A: E.38, S.41, R.42, W.53
Ligand excluded by PLIPFMT.33: 0 residues within 4Å:- (No contacts)
Ligand excluded by PLIPFMT.34: 2 residues within 4Å:- Chain A: R.103
- Ligands: FMT.35
Ligand excluded by PLIPFMT.35: 4 residues within 4Å:- Chain A: D.100, R.103, H.228
- Ligands: FMT.34
Ligand excluded by PLIPFMT.36: 4 residues within 4Å:- Chain A: R.103, R.106, D.226, L.229
Ligand excluded by PLIPFMT.37: 2 residues within 4Å:- Chain A: D.227, H.228
Ligand excluded by PLIPFMT.38: 3 residues within 4Å:- Chain A: R.103, R.106
- Ligands: FMT.40
Ligand excluded by PLIPFMT.39: 1 residues within 4Å:- Ligands: FMT.41
Ligand excluded by PLIPFMT.40: 1 residues within 4Å:- Ligands: FMT.38
Ligand excluded by PLIPFMT.41: 1 residues within 4Å:- Ligands: FMT.39
Ligand excluded by PLIPFMT.42: 1 residues within 4Å:- Chain A: E.213
Ligand excluded by PLIPFMT.43: 4 residues within 4Å:- Chain A: V.145, V.150, R.172, E.401
Ligand excluded by PLIPFMT.44: 1 residues within 4Å:- Chain A: R.183
Ligand excluded by PLIPFMT.45: 6 residues within 4Å:- Chain A: R.172, D.176, H.246, E.247, V.250, K.392
Ligand excluded by PLIPFMT.46: 5 residues within 4Å:- Chain A: R.207, P.211, T.212, G.217, L.221
Ligand excluded by PLIPFMT.47: 7 residues within 4Å:- Chain A: R.62, H.346, I.347, G.350, H.351, H.355
- Ligands: FMT.4
Ligand excluded by PLIPFMT.48: 5 residues within 4Å:- Chain A: R.121, Q.360, R.363, L.364, Q.367
Ligand excluded by PLIPFMT.49: 4 residues within 4Å:- Chain A: D.129, A.372, R.375, R.376
Ligand excluded by PLIPFMT.50: 5 residues within 4Å:- Chain A: P.274, A.275, V.277, S.371, R.375
Ligand excluded by PLIPFMT.51: 0 residues within 4Å:- (No contacts)
Ligand excluded by PLIPFMT.52: 1 residues within 4Å:- Chain A: K.390
Ligand excluded by PLIPFMT.53: 5 residues within 4Å:- Chain A: H.23, A.24, H.258, V.386, W.391
Ligand excluded by PLIPFMT.54: 1 residues within 4Å:- Chain A: D.381
Ligand excluded by PLIPFMT.55: 3 residues within 4Å:- Chain A: M.58, S.59, R.62
Ligand excluded by PLIPFMT.56: 0 residues within 4Å:- (No contacts)
Ligand excluded by PLIPFMT.57: 0 residues within 4Å:- (No contacts)
Ligand excluded by PLIPFMT.58: 2 residues within 4Å:- Chain A: A.73
- Ligands: FMT.15
Ligand excluded by PLIPFMT.59: 3 residues within 4Å:- Chain A: R.116, E.119, M.120
Ligand excluded by PLIPFMT.60: 4 residues within 4Å:- Chain A: P.122, R.125, S.126, D.129
Ligand excluded by PLIPFMT.61: 2 residues within 4Å:- Chain A: R.375, R.376
Ligand excluded by PLIPFMT.62: 8 residues within 4Å:- Chain A: P.22, S.292, K.392, Q.393, G.394, M.395, I.397
- Ligands: FMT.21
Ligand excluded by PLIPFMT.63: 1 residues within 4Å:- Chain A: D.195
Ligand excluded by PLIPFMT.64: 0 residues within 4Å:- (No contacts)
Ligand excluded by PLIPFMT.65: 7 residues within 4Å:- Chain A: P.88, E.89, G.92, A.95, F.296
- Ligands: QR8.2, RAM.3
Ligand excluded by PLIPFMT.66: 1 residues within 4Å:- Chain A: A.387
Ligand excluded by PLIPFMT.67: 2 residues within 4Å:- Chain A: A.13
- Ligands: FMT.69
Ligand excluded by PLIPFMT.68: 1 residues within 4Å:- Ligands: FMT.69
Ligand excluded by PLIPFMT.69: 2 residues within 4Å:- Ligands: FMT.67, FMT.68
Ligand excluded by PLIPFMT.70: 2 residues within 4Å:- Chain A: R.62, P.345
Ligand excluded by PLIPFMT.71: 3 residues within 4Å:- Chain A: E.342, R.343, N.344
Ligand excluded by PLIPFMT.72: 5 residues within 4Å:- Chain A: L.276, A.279, F.339, H.340, R.341
Ligand excluded by PLIPFMT.73: 3 residues within 4Å:- Chain A: E.89, P.90, D.91
Ligand excluded by PLIPFMT.74: 0 residues within 4Å:- (No contacts)
Ligand excluded by PLIP- 1 x NA: SODIUM ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Parisi, G. et al., Dissecting the Cytochrome P450 OleP Substrate Specificity: Evidence for a Preferential Substrate. Biomolecules (2020)
- Release Date
- 2020-10-21
- Peptides
- Cytochrome P-450: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.28 Å
- Oligo State
- monomer
- Ligands
- 1 x HEM: PROTOPORPHYRIN IX CONTAINING FE(Non-covalent)
- 1 x QR8: (3~{R},4~{S},5~{R},6~{S},7~{S},9~{S},11~{R},12~{S},13~{R},14~{R})-3,5,7,9,11,13,14-heptamethyl-4,6,12-tris(oxidanyl)-1-oxacyclotetradecane-2,10-dione(Non-covalent)
- 1 x RAM: alpha-L-rhamnopyranose(Non-covalent)
- 70 x FMT: FORMIC ACID(Non-functional Binders)
- 1 x NA: SODIUM ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Parisi, G. et al., Dissecting the Cytochrome P450 OleP Substrate Specificity: Evidence for a Preferential Substrate. Biomolecules (2020)
- Release Date
- 2020-10-21
- Peptides
- Cytochrome P-450: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A